HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT

Clare Gilham,1 Alexandra Sargent,2 Henry C Kitchener3 and Julian Peto1*

1Non-Communicable Disease Epidemiology Unit, London School of Hygiene & Tropical Medicine, London, UK
2Department of Virology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
3School of Cancer and Sciences, University of Manchester, St Mary’s Hospital, Manchester, UK

*Corresponding author julian.peto@lshtm.ac.uk

Declared competing interests of authors: Henry Kitchener reports grants from the University of Manchester during the conduct of the study. He is chairperson of the Advisory Committee for Cervical Screening (Public Health England) as well as of the National HPV Pilot Steering Group. Any views expressed in this report are those of the authors and not of Public Health England.

Published June 2019
DOI: 10.3310/hta23280

Plain English summary

ARTISTIC RCT: follow-up
Health Technology Assessment 2019; Vol. 23: No. 28
DOI: 10.3310/hta23280

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Human papillomavirus (HPV) causes cervical cancer. The latest scientific evidence shows that screening for HPV is better than screening for abnormal cytology with a ‘smear’ test, so HPV testing is being rolled out nationally. The main disadvantage is that more women will test positive and be referred for further tests. Most infections are harmless and clear without treatment, and balance must be achieved so that women who progress to CIN3 (pre-cancer) are identified but that unnecessary referral and anxiety for women is minimised.

A Randomised Trial In Screening To Improve Cytology (ARTISTIC) recruited 24,510 women attending for cervical screening in Greater Manchester in 2001–3. Cervical samples taken at recruitment and again at screening 3 and 6 years later were tested for HPV. The women then returned to routine screening. We have followed them through national screening records and cancer registration until the end of 2015.

By comparing the HPV results taken at entry with those collected 3 years later, we can categorise HPV infections into new and persistent. We have found that the CIN3 risk in women with persistent infections is about six times higher than in women with new infections, which in turn is about 30 times higher than in women with no infection.

About three-quarters of women with HPV infection but no abnormal cells clear their infections within 3 years. Their risk of pre-cancer within 3 years is low (1.5%) and so intensive follow-up is unnecessary. Moreover, 40% of those who remain human papillomavirus positive (HPV+) have cleared their initial infection and acquired a new infection, meaning that they are also at much lower risk of disease than those with a persistent infection. The current practice in the national pilot study of annual repeat testing and referral of anyone who is still HPV+ after 2 years may, therefore, be too conservative.

We have also shown that the CIN3 risk after 10 years in women testing negative for HPV is similar to the risk after about 3 years in women testing negative for cytology. This means that screening intervals could be extended for women testing negative for HPV.
Health Technology Assessment

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 98/04/501. The contractual start date was in September 2013. The draft report began editorial review in April 2017 and was accepted for publication in November 2017.

The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gilham et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).